Azithromycin Synergizes with Cationic Antimicrobial Peptides to Exert Bactericidal and Therapeutic Activity Against Highly Multidrug-Resistant Gram-Negative Bacterial Pathogens  by Lin, Leo et al.
EBioMedicine 2 (2015) 690–698
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comOriginal ArticleAzithromycin Synergizes with Cationic Antimicrobial Peptides to Exert
Bactericidal and Therapeutic Activity Against Highly Multidrug-Resistant
Gram-Negative Bacterial PathogensLeo Lin a,⁎, Poochit Nonejuie b,1, Jason Munguia a,1, Andrew Hollands a, Joshua Olson a, Quang Dam a,
Monika Kumaraswamy c, Heriberto Rivera Jr. d, Ross Corriden a, Manfred Rohde e, Mary E. Hensler a,
Michael D. Burkart d, Joe Pogliano b, George Sakoulas a, Victor Nizet a,f,g,⁎⁎
a Department of Pediatrics, University of California, San Diego, La Jolla, CA 92093, USA
b Division of Biological Sciences, University of California, San Diego, La Jolla, CA 92093, USA
c Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA
d Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla CA 92093, USA
e Central Facility for Microscopy, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany
f Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093, USA
g Rady Children's Hospital, San Diego, CA 92123, USA⁎ Corresponding author.
⁎⁎ Correspondence to: V. Nizet, Department of Pediatri
Diego, La Jolla, CA 92093, USA.
E-mail addresses: l2lin@ucsd.edu (L. Lin), vnizet@ucsd
1 These authors contributed equally.
http://dx.doi.org/10.1016/j.ebiom.2015.05.021
2352-3964/© 2015 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 18 May 2015
Received in revised form 21 May 2015
Accepted 21 May 2015
Available online 10 June 2015
Keywords:
Azithromycin
Macrolides
Antimicrobial peptides
Cathelicidin
LL-37
Antibiotic resistance
Colistin
Pseudomonas aeruginosa
Acinetobacter baumannii
Klebsiella pneumoniaeAntibiotic resistance poses an increasingly grave threat to the public health. Of pressing concern, rapid spread of
carbapenem-resistance among multidrug-resistant (MDR) Gram-negative rods (GNR) is associated with few
treatment options and highmortality rates. Current antibiotic susceptibility testing guiding patient management
is performed in a standardized manner, identifying minimum inhibitory concentrations (MIC) in bacteriologic
media, but ignoring host immune factors. Lacking activity in standard MIC testing, azithromycin (AZM), the
most commonly prescribed antibiotic in the U.S., is never recommended for MDR GNR infection. Here we report
a potent bactericidal action of AZM against MDR carbapenem-resistant isolates of Pseudomonas aeruginosa, Kleb-
siella pneumoniae, and Acinetobacter baumannii. This pharmaceutical activity is associated with enhanced AZM
cell penetration in eukaryotic tissue culturemedia and strikingmulti-log-fold synergieswith host cathelicidin an-
timicrobial peptide LL-37 or the last line antibiotic colistin. Finally, AZMmonotherapy exerts clear therapeutic ef-
fects in murine models of MDR GNR infection. Our results suggest that AZM, currently ignored as a treatment
option, could beneﬁt patients with MDR GNR infections, especially in combination with colistin.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Hospital-acquired infections, half caused by drug-resistant bacteria
(Mauldin et al., 2010), cause ~99,000 deaths annually and increase
healthcare costs by $5–10 billion in the U.S. alone (Peleg and Hooper,
2010). Recent reports by the U.S. Centers for Disease Control and Pre-
vention (CDC, 2013) and the World Health Organization (WHO, 2014)
describe this ever-worsening antibiotic resistance crisis, highlighting
the “urgent threat” of emerging carbapenem-resistant Gram-negative
rods (GNRs) that forebode the entry of humanmedicine into a “post-an-
tibiotic era”. Rapid spread of carbapenem resistance in Pseudomonascs, University of California, San
.edu (V. Nizet).
. This is an open access article underaeruginosa (PA), Klebsiella pneumoniae (KP) and Acinetobacter
baumannii (AB) is of particular concern as effective antibiotic candidates
are currently lacking in the development pipeline (Diene and Rolain,
2014).
Unconventional approaches to infectious disease treatment are
gaining more attention, including virulence factor inhibition, bacterio-
phage therapy, probiotics and immune boosting (Cegelski et al., 2008;
Hancock et al., 2012). Along these lines, we have probed interactions
of conventional antibioticswith antimicrobial effectors of the innate im-
mune system, with encouraging results. Drugs with no direct activity in
standardminimum inhibitory concentration (MIC) testing nevertheless
sensitizedmultidrug-resistant (MDR) bacterial pathogens to human an-
timicrobial peptide killing in vitro, e.g., nafcillin vs. methicillin-resistant
Staphylococcus aureus (MRSA) or ampicillin vs. vancomycin-resistant
Enterococcus (VRE), and contributed to clinical resolution in refractory
infections (Sakoulas et al., 2012, 2014).the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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simpleMIC testing overlooks potential synergies with cationic antibiotics
(e.g., daptomycin) and host AMPs (e.g., human cathelicidin LL-37) that
promote bactericidal activity in vitro and bacterial clearance in patients
(Sakoulas et al., 2012, 2014). We asked whether similar phenomena
could be identiﬁed in MDR-GNRs to challenge conventional antibiotic
treatment paradigms. AZM, the most commonly prescribed antibiotic in
the U.S. (51.5million in 2010) (Hicks et al., 2013), is never recommended
for inpatient treatment of serious GNR infections because of poor or ab-
sent in vitro activity by standardMIC testing in bacteriologicmedia. How-
ever, antibacterial activity of AZM is enhanced in mammalian tissue
culture media vs. standard bacteriologic media (Buyck et al., 2012), a
ﬁnding reminiscent of observations we made for LL-37 (Dorschner
et al., 2006), prompting us to examine its interaction with MDR GNRs
more closely.
2. Materials and Methods
2.1. Bacterial Strains
P. aeruginosa (PA) strain PA01, K. pneumoniae (KP) strain K700603,
and A. baumannii (AB) strain AB19606 were obtained from the
American Type Culture Collection (ATCC). Human clinical MDR isolates
PA P4 (lung) and KP K1100 (lung) (Fair et al., 2012) were obtained from
a tertiary academic hospital in the New York metropolitan area. MDR-
AB AB5075 (bone) (Zurawski et al., 2012) was obtained from Walter
Reed Army Medical Center. All three MDR strains were independently
identiﬁed and subject to antibiotic susceptibility testing by the clinical
microbiology laboratory at the San Diego Veterans Affairs Hospital
(table S1). AdditionalMDRGNR clinical isolates testedwere also obtain-
ed from a tertiary academic hospital in theNewYorkmetropolitan area,
except for PA USCD P1, whichwas obtained from the UC San Diego hos-
pital system. Bacteriawere grown overnight in Luria Broth (LB), glycerol
was added (30% ﬁnal), and stocks stored at−80 °C. Fresh colonies were
streaked onto LB plates each week for all experiments.
2.2. Antibiotics and Antimicrobial Peptides
For in vitro studies, AZM, colistin sulfate, and ciproﬂoxacinwere pur-
chased from Sigma-Aldrich; erythromycin and clarithromycin were
purchased from Fischer Scientiﬁc. Stock solutions were prepared in
phosphate buffered saline (PBS) at 2560 mg/L for the macrolide antibi-
otics, 1000 mg/L for colistin, and 10,000 mg/L for ciproﬂoxacin. Trace
amounts of glacial acetic acid were used to prepare AZM, erythromycin
and clarithromycin stocks for complete solubility (Barry et al., 2004). LL-
37 and TAMRA-tagged LL-37 were purchased from the American Pep-
tide Company; stock solutions were prepared in molecular quality
water (Corning Cellgro) at 640 μM and 320 μM, respectively, and stored
at−80 °C. For in vivo studies, AZM for human injection (Sagent Phar-
maceuticals) was reconstituted per manufacturer's guidelines (AZM
Package Insert, 2013). Pooled human serum was obtained from six
healthy consented lab volunteers under a protocol approved by the
UCSD Human Research Protection Program and immediately aliquoted
and stored at−80 °C.
2.3. Reagents
Mueller–Hinton Broth (MHB, Spectrum Chemicals) was supple-
mented with CaCl2 and MgCl2 to make cation-adjusted MHB (Ca-
MHB) — ﬁnal cation concentrations (20–25 mg/L Ca2+ and
10–12.5 mg/L Mg2+). Luria Broth base (LB) was purchased from Hardy
Diagnostics. RPMI-1640 was purchased from Invitrogen. Clear phenol
free RPMI-1640 used for microscopy studies was purchased from
Corning Cellgro. 1-N-phenylnaphthylamine (NPN) was purchased
from Sigma-Aldrich and a fresh stock of 500 μM in acetone was made
each week.2.4. MIC Determinations
MIC values for AZM, erythromycin, clarithromycin, ciproﬂoxacin,
colistin, and LL-37were determined using brothmicrodilution in accor-
dance with the Clinical Laboratory Standards Institute (CLSI) guidelines
using Ca-MHBmedia, the recommended bacteriologic broth, or eukary-
otic cell culture media RPMI-1640 supplemented with 5% LB (Sakoulas
et al., 2014).
2.5. Time-Kill Curves and Serum Survival Assays
Time-kill studies, ±20% pooled human serum, were performed as
previously described (Haste et al., 2011). Bacteria were grown overnight
in LB at 37 °C with shaking. Bacterial stocks in PBS were prepared by
washing the overnight cultures twice with PBS via centrifugation at
3220 ×g at room temperature with a ﬁnal re-suspension in PBS to an
OD600 = 0.40. Bacterial stocks in PBS were diluted in Ca-MHB or 5% LB-
RPMI to an initial inoculum of 1 × 106 CFU/mL (standard time-kill) or
5 × 104 CFU/mL (serum survival). AZM, erythromycin, clarithromycin,
colistin, and LL-37 stocks were diluted in Ca-MHB or 5% LB-RPMI to the
assay concentrations indicated. For serum studies, AZM 0.5 mg/L was
chosen in order to approximate human plasma concentrations upon in-
travenous administration of 500 mg of AZM (AZM Package Insert,
2013). Assays were conducted in triplicate in a ﬁnal volume of 200 μL
in 96-well round bottom plates (Costar) ±20% pooled human serum.
The 96-well plates were wrapped in parafﬁn and placed in a shaking
incubator at 37 °C. Aliquots were collected at the indicated times and
serially diluted for CFU enumeration; limit of detection = 100 CFU/mL.
2.6. Electron Microscopy of Bacterial Gross Morphology
Transmission electron microscopy was performed essentially as
described (Sato, 1968). MDR-AB was grown overnight in LB at 37 °C
with shaking. Bacterial stocks in PBS were prepared by washing the
overnight cultures twice with PBS and resuspending in PBS to
OD600 = 0.40. Then 2.5 mL of each bacterial stock was added to
47.5 mL of Ca-MHB or RPMI + 5% LB media pre-warmed to 37 °C. For
treatment, the AZM stock was diluted to a concentration of 0.5 mg/L
in the ﬁnal volume of 50 mL. 50 mL cultures were placed in a shaking
incubator at 37 °C for 2 h. Cultures were then centrifuged at 3220 × g
at room temperature for 10 min. The supernatant was aspirated and
bacterial pellets re-suspended in 1 mL of PBS. These 1 mL samples
were immersed in modiﬁed Karnovsky's ﬁxative (2.5% glutaraldehyde
and 2% paraformaldehyde in 0.15 M sodium cacodylate buffer, pH 7.4)
for at least 4 h, post-ﬁxed in 1% osmium tetroxide in 0.15 M cacodylate
buffer for 1 h, and stained en bloc in 2% uranyl acetate for 1 h. Samples
were dehydrated in ethanol, embedded in Durcupan epoxy resin
(Sigma-Aldrich), sectioned at 50–60 nmon a Leica UCT ultramicrotome,
and picked up on Formvar and carbon-coated copper grids. Sections
were stained with 2% uranyl acetate for 5 min and Sato's lead stain for
1 min. Grids were viewed using a Tecnai G2 Spirit BioTWIN transmis-
sion electron microscope and photographs were taken with an Eagle
4 k HS digital camera (FEI). Images were taken from multiple random
ﬁelds at 1200×, 2900×, 23,000×; and gross morphology was analyzed
in a blinded fashion.
2.7. Fluorescence Microscopy for MDR-AB Cytological Proﬁling
The ﬂuorescencemicroscopy studies forMDR-ABwere performed as
previously described (Nonejuie et al., 2013). These microscopy studies
required higher concentrations of AZM because the concentration of
MDR-AB usedwas 100× higher (5 × 107 CFU/mL) compared to the con-
centration used in theMIC assays (5× 105 CFU/mL). All AZM concentra-
tions used in these studies are pharmacologically obtainable in human
tissue. Single MDR-AB colonies were picked from LB plates and grown
in LB or RPMI + 5% LB overnight. Overnight cultures were then diluted
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0.20was reached, antibioticswere added to exponentially growing bac-
teria. Cultureswere placed on a shaker at 30 °C and collected after 1 h or
2 h and stained with 1 μg/mL FM4-64 2 μg/mL DAPI, and 0.5 μMSYTOX-
Green (Molecular Probes/Invitrogen). In the case of NBD-tagged AZM,
SYTOX-Green dye was omitted and cell cultures were washed with
fresh media before staining. Stained cultures were centrifuged at
300 × g for 30 s in amicrocentrifuge and resuspended in approximately
5% original volume. 3 μL of concentrated cells were transferred onto a
pad containing 1.2% agarose and 20% LB medium for microscopy. The
exposure time of each excitation was the same for each experimental
replicate included in the statistical analysis of all treatments. All images
were analyzed using ImageJ software v1.48f and CellProﬁler 2.0. Fluo-
rescence intensity analysis was performed on non-deconvolved images.
Average DAPI, SYTOX Green, or NBD intensity per cell was measured
and respective background intensities subtracted. Finally, the intensity
of treated cells was normalized by the intensity of untreated cells
from the same experiment set, making intensity data from different ex-
perimental sets comparable as relative intensity. Protein translation in-
hibition phenotype was automatically calculated by the degree of DNA
condensation deﬁned by the ratio of DNA area over total cell membrane
area. Cells with a ratio less than half of those calculated from untreated
control cells were considered to have condensed toroid nucleoids
(Nonejuie et al., 2013). Fluorescence intensity and protein translation
inhibition population data were obtained by counting N500 cells from
random microscopy ﬁelds per condition per experimental replicate,
with 3 independent replicates. The ﬂuorescence microscopy for LL-37
cell binding was performed in a similar manner except that after the
MDR-AB cultures were incubated in 0.5 mg/L of AZM versus control
for 2 h, 2 μM of TAMRA-tagged LL-37 was added and the cultures incu-
bated for an additional 30 min before staining and analysis.
2.8. Mouse AZM Dosing
Standard human dosing of AZM is 500 or 1000 mg administered
orally or intravenously q 24 h (7.7 or 15 mg/kg for an average adult).
Mice metabolize AZM 29 times faster than humans (Hoffmann et al.,
2007), and 50 mg/kg AZM given subcutaneously to mice approximates
500mg given intravenously to human patients (Beigelman et al., 2009).
We therefore chose to administer 50 or 100mg/kg AZM subcutaneously
in our murine infection models once every 24 h.
2.9. Mouse Pneumonia Models
The murine pneumonia mode was performed with slight modiﬁca-
tions as previously described (Revelli et al., 2012). All intratracheal
infections were performed in a blinded fashion with respect to AZM or
PBS treatment. For the MDR-AB lung infection model, 8-wk-old female
C57Bl/6J mice (Jackson Labs) were used, divided randomly into
matched treatment and control groups. MDR-AB cultures were grown
overnight in LB at 37 °Cwith shaking and then re-grown in themorning
in fresh LB to a concentration of OD600 = 0.40. Bacteria were washed
twice with PBS via centrifugation at 3220 ×g at room temperature and
concentrated in PBS to yield 5 × 106 CFU in the 30 μL, the inoculation
volume. Mice were anesthetized with 100 mg/kg ketamine and
10 mg/kg xylazine. Once sedated, the vocal chords were visualized
using an operating otoscope (Welch Allyn) and 30 μL of bacteria or
PBS was instilled into the trachea during inspiration using a plastic gel
loading pipette tip. Mice were placed on a warmed pad for recovery
and given one subcutaneous dose of 50 mg/kg or 100 mg/kg human
AZM for injection reconstituted in PBS. Mice were sacriﬁced with CO2
for bacterial counts or for analysis of their broncho alveolar ﬂuid
(BALF) 24 h after infection. To enumerate total surviving bacteria in
the lungs, both lung lobes were removed and placed in a 2 mL sterile
micro tube (Sarstedt) containing 1 mL of PBS and 1 mm silica beads
(Biospec). Lungs were homogenized by shaking twice at 6000 rpm for1 min using a MagNA Lyser (Roche), with the specimens placed on ice
as soon as they were harvested. Aliquots from each tube were serially
diluted for CFU enumeration on LB plates. For BALF collection and anal-
ysis, an incision was made in the trachea and the lungs slowly inﬂated
with 700 μL of chilled PBS using a 1 mL syringe topped with a 20G
blunt needle tip (Harvard Apparatus). The PBS was slowly withdrawn,
and the recovered BALF was spun at 1200 ×g at 4 °C for 10 min. The
supernatant (350 μL) was analyzed for the mouse pro-inﬂammatory
cytokines mIL-1β, mIL-6, and mMIP-2 (R&D Systems ELISA Kits). Cell
pelletswere resuspended in chilled PBS to aﬁnal volume of 500 μL. Sam-
ples were enumerated with a hemocytometer for total leukocyte num-
ber. 100 μL was spun onto glass microscopy slides using a Shandon
Cytospin 3 (Thermo Scientiﬁc). Dry glass slides were stained with
Wright–Giemsa stain, and N200 leukocytes were counted per animal
using a light microscope for neutrophil and alveolar macrophage enu-
meration. For the MDR-AB lung infection survival experiment 5 × 107
CFU were given in 36 μL of PBS. One dose of 100 mg/kg AZM or 100 μL
of PBS controlwas given subcutaneously immediately after the infection
(time 0) and a second dose was given 24 h later. The MDR KP and PA
intra-tracheal murine lung infections were performed in a similar man-
ner except that 8-week-old female CD1 mice (Charles River Labs) were
used and the animals were sacriﬁced 36 h after infection for enumera-
tion of surviving bacteria. The inocula for MDR-KP and MDR-PA infec-
tion were 1.5 × 107 CFU and 1 × 107 CFU in 40 μL of PBS, respectively.
The AB foreign body infection studies were performed as previously de-
scribed (Kadurugamuwa et al., 2003). Outcome assessment was not
blinded to AZM vs. PBS groups, but these involved objective (e.g., mor-
tality, bacterial counts, cytokine levels) not subjective data. All animal
studies were performed under protocols approved by the UCSD Institu-
tional Animal Use and Care Committee.
2.10. Statistical Analysis
All statistics were performed using GraphPad Prism version 5.0 2-
way ANOVA, 1-way ANOVA, two tailed Student's t-test, and log-rank
test were performed as described in each ﬁgure legend.
3. Results
3.1. AZM is Highly Bactericidal vs. MDR GNRs in Tissue Culture Media
For each opportunistic GNR pathogen (PA, KP and AB) we tested a
commonmodel strain plus a corresponding extremelyMDR human iso-
late (Supplementary Table 1). AZM MICs were determined by Clinical
and Laboratory Standard Institute (CLSI) brothmicrodilutionmethodol-
ogy (CLSI, 2008) using either the recommended cation-adjusted
Mueller–Hinton broth (Ca-MHB) or eukaryotic cell culture media
RPMI-1640 supplementedwith 5% Luria broth (RPMI+5% LB) (Supple-
mentary Table 2). In every case, a ≥30-fold reduction inMICwas seen in
RPMI + 5% LB vs. Ca-MHB, rendering all organisms susceptible by the
accepted breakpoint of ≤8mg/L for Campylobacter and S. aureus. In con-
trast, no marked changes in MIC of ﬂuoroquinolone ciproﬂoxacin were
observed formodel strains (all sensitive) orMDR clinical isolates (all re-
sistant) in RPMI + 5% LB vs. Ca-MHB (Supplementary Table 2). A simi-
larly profound reduction in MIC in RPMI + 5% LB vs. Ca-MHB was also
observed for an expanded panel of 11 additional MDR GNR clinical iso-
lates (Supplementary Table 3). Two additional macrolides, erythromy-
cin and clarithromycin, also demonstrated dramatically higher activity
against MDR GNRs in RPMI + 5% LB versus Ca-MHB, although AZM
was the most potent of the macrolides tested (Supplementary
Table 2). Time-kill curves determined the mean bactericidal concentra-
tion (MBC, reduction in CFUby 2log10) of AZMagainst theMDR-GNRs in
RPMI + 5% LB media (Fig. 1A–C). With an initial inoculum of
1 × 106 CFU/mL, the MBC of AZM against MDR-PA, -KP and -AB were
4 mg/L (MIC = 2 mg/L), 1 mg/L (MIC = 1 mg/L) and 0.5 mg/L
(MIC = 0.5 mg/L) respectively. While all three MDR-GNRs achieved
Fig. 1. AZM bactericidal activity against GNRs in eukaryotic media and human serum. AZM concentrations=mg/L. (A–C) Time-kill curves demonstrating AZMMBC against MDR PA, KP,
andAB in eukaryoticmedia (RPMI+5%LB) vs. bacteriologic broth (Ca-MHB).Mean of triplicates from3 independent experiments± SEM ***P b 0.001; two-wayANOVA; limit of detection
50CFU/mL. (D–F) 5× 104 CFU/mL bacteria incubated at 37 °C for 2 h inRPMI alone (0% serum), AZM0.5, 20% serum, andAZM0.5+20% serum. Data show%viable CFU vs. initial inoculum;
mean of triplicates from 3 independent experiments ± SEM. *P b 0.05, ***P b 0.001; two-tailed Student's t-test. (G) MDR AB (5 × 107 CFU/mL) grown in Ca-MHB vs. RPMI + 5% LB were
treated for 2 hwith AZM2 and stained forﬂuorescencemicroscopy: FM4-64 (red cellmembrane stain), DAPI (blueDNA stain), “T” denotes toroid shaped nucleoid. For ready visualization,
the concentration of MDR ABwas 100-fold higher than inMIC assays; thus a higher concentration AZMwas used. (H) Transmission electron microscopy images representative of 2 inde-
pendent experiments with logarithmic growth phase MDR AB treated for 2 h with AZM 0.5; C = Capsule; CM = Cell Membrane; Pep = Peptidoglycan; OM= Outer Membrane; R =
Ribosomes. (I) Bar graphs generated from unbiased software analysis of multiple random microscopy ﬁelds with N500 cells counted per condition per experimental replicate. Data rep-
resentative of 3 independent experiments plotted asmean± SEM; additionalmicroscopy details inMaterials andmethods section. ***P b 0.001; one-way ANOVA and two tailed Student's
t-test.
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markedly more bactericidal in the eukaryotic tissue culture media
(Fig. 1A–C): a striking 6-logfold increased killing for KP and AB and
2-logfold increased killing for PA. For MDR-PA and -AB, AZM 4 mg/L
(b1/16MIC) resulted in signiﬁcant killing even in Ca-MHBonce bacteria
reached stationary growth phase (Fig. 1A and C), consistent with re-
ported AZM bactericidal activity against stationary phase antibiotic-
sensitive PA (Imamura et al., 2005). AZM activity against all three
MDR pathogens was further enhanced in the presence of 20% human
serum (Fig. 1D–F), mirroring a prior observation of serum potentiation
of AZM activity against Escherichia coli and S. aureus (Pruul and
McDonald, 1992). Serial passage of all threeMDR pathogens for 10 con-
secutive days at sub-minimum inhibitory concentrations of AZM in
RPMI + 5% LB media demonstrated no increase in resistance to AZM
over this time frame (Fig. S1).3.2. Enhanced AZM Permeability in Tissue Culture Media Triggers Nucleoid
Collapse
AZM binds the 50S large ribosomal subunit at the polypeptide exit
tunnel, blocking protein synthesis (Kannan et al., 2012). We employed
ﬂuorescence microscopy-based bacterial cytological proﬁling (BCP)(Nonejuie et al., 2013) of MDR-AB to identify the cellular pathway
perturbed by AZM treatment in RPMI + 5% LB media but not Ca-MHB.
BCP revealed that nucleoid collapse into a low energy toroid shape, a
hallmark of protein synthesis inhibition (Nonejuie et al., 2013;
Zusman et al., 1973), was markedly increased in AB treated with AZM
in RPMI + 5% LB (Fig. 1G), a ﬁnding corroborated by transmission elec-
tronmicroscopy of treated cells (Fig. 1H). Increased staining intensity of
the DNA dye DAPI in RPMI + 5% LB vs. Ca-MHB even without AZM sug-
gested increased membrane permeability in the cell culture media
(Fig. 1I). DAPI staining of MDR-AB was further increased upon AZM
treatment, possibly reﬂecting impaired efﬂux pump function seen in
antibiotic-sensitive PA treated with AZM in RPMI (Buyck et al., 2012).3.3. Colistin PermeabilizationMarkedly Potentiates AZM Bactericidal Activ-
ity vs. MDR GNRs
Colistin is an antibiotic of last resort for carbapenem-resistant GNR
infections (Biswas et al., 2012), but its use is complicated by marked
dose-dependent nephrotoxicity and uncertainties in optimal dosing
(Spapen et al., 2011). We asked whether AZM could act synergistically
with colistin, even in standard Ca-MHB media in which AZM alone has
little or no activity. At a sub-MIC (Supplementary Table 2) and
694 L. Lin et al. / EBioMedicine 2 (2015) 690–698pharmacologically attainable dose of each drug, marked synergy
(Leonard, 2012) of AZM+ colistin was observed against MDR-PA (addi-
tional reduction in CFU by 2log10), -KP (by 5log10) and -AB (by 3log10)
(Fig. 2A–C). BCP showed strongly increased DAPI staining and toroid nu-
cleoid morphology in MDR-AB treated with AZM + colistin vs. either
agent alone (Fig. 2D and E). Amembrane permeability effect was corrob-
orated as bacterial cell entry of the ﬂuorescent dye SYTOX green (MW=
600Da vs. 749Da for AZM)was increased 3-fold by colistin and 4-fold by
colistin + AZM (Fig. 2D and G). Indeed, colistin markedly enhanced
entry of ﬂuorescently tagged AZM (NBD-AZM (Matijasic et al., 2012))
into MDR-AB cells (Fig. 2F and G). A cationic peptide antibiotic, colistin
permeabilizes the bacterial cell envelope (Koike et al., 1969), andwe sur-
mise it facilitates AZM entrywhereupon the latter drug can exert its clas-
sical ribosomal protein synthesis activity. Erythromycin and
clarithromycin also showed signiﬁcant synergy with colistin (Fig. S2),
with azithromycin the most potent of the three macrolides tested.
3.4. Pronounced Bactericidal Synergy of AZM with Human Cathelicidin LL-
37 vs. MDR GNRs
Endogenous cationic AMPs are critical tomammalian innate immuni-
ty against invasive bacterial infection (Gallo and Hooper, 2012). GivenFig. 2. Colistin synergizeswith AZMby increasingGNR outermembrane permeability. All assays
effect of AZM, colistin, or both in combination against MDR PA, KP and AB. Data plotted are
***P b 0.001; two-way ANOVA. (D and F) Growth phase MDR AB (5 × 107 CFU/mL) treated for
for ﬂuorescence microscopy: FM4-64 (red cell membrane stain), DAPI (blue DNA stain), SYTOX
nucleoid. DAPI blue DNA stain present in “Untreated” and “AZM4” panels. Since signal from all c
10-fold higher DAPI signal intensity, blue signal was reduced equally across all four displayed D
with high DAPI signal intensity. (E and G) Bar graphs were generated from unbiased software
experimental replicate. Data representative of 3 independent experiments and plotted as the
***P b 0.001; one-way ANOVA.the observed synergy of AZM with the bacterial-derived AMP colistin,
we hypothesized that AZM could be potentiated by LL-37, a cationic
AMP produced abundantly by phagocytic and epithelial cells during in-
fection (Cederlund et al., 2011). At sub-MIC doses (Supplementary
Table 2), marked synergy of AZM + LL-37 was observed against MDR-
PA (additional reduction in CFU by 4log10), KP (7log10) and AB (4log10)
(Fig. 3A–C). For MDR-AB, AZM 0.0625 mg/L (1/8th MIC) + 1 μM LL-37
(1/4th MIC) resulted in N99% killing within 4 h. BCP showed increased
DAPI staining and toroid morphology of nucleoids in MDR-AB treated
with AZM+ LL-37 vs. either agent alone (Fig. 3D and E). SYTOX green
entry into the bacterial cell was increased 3-fold in the presence of LL-
37 and 5-fold in the presence of LL-37 + AZM (Fig. 3D and G). LL-37
also markedly enhanced entry of NBD-AZM into MDR-AB cells (Fig. 3 F
and G), consistent with the known activity of LL-37 to interfere with
GNR cell wall biogenesis and cytoplasmic membrane integrity (Sochacki
et al., 2011). Studies with 1-N-phenylnaphthylamine (NPN), a validated
marker for outer membrane permeability of GNRs (Helander and
Mattila-Sandholm, 2000), veriﬁed that sub-MIC concentrations of colistin
or LL-37 increased outer membrane permeability of the MDR-AB strain
(Fig. S3). Interestingly, AZM pretreatment of MDR-AB signiﬁcantly en-
hanced binding of TAMRA-tagged LL-37 to the bacterial outermembrane,
suggesting bidirectional synergy (Fig. S4).conducted using the bacteriologicmedia Ca-MHB. (A–C) Time-kill curves demonstrate the
mean ± SEM and represent the average of triplicates from 3 independent experiments.
1 h with AZM (unlabeled or NBD-tagged), colistin, or a combination of both, then stained
Green (green DNA stain), and NBD-AZM (green NBD-tagged AZM), “T”= toroid shaped
onditionswas normalized to untreated controls and “AZM+Colistin” treated bacteria had
API panels to prevent washout and enable visualization of the toroid structures in the cells
analysis of multiple randommicroscopy ﬁelds with N500 cells counted per condition per
mean ± SEM — additional microscopy details in methods section. *P b 0.05, **P b 0.01,
Fig. 3. Cationic AMP LL-37 synergizes with AZM by increasing the outer membrane permeability of MDR-GNRs. All assays conducted using the eukaryotic media RPMI + 5% LB. (A–C)
Time-kill curves demonstrating effects of AZM, LL-37, or both in combination against MDR PA, KP, and AB. Data plotted are mean ± SEM and represent the average of triplicates from 3
independent experiments. ***P b 0.001; two-way ANOVA. Limit of detection = 50 CFU/mL (D and F) Logarithmic growth phase MDR AB (5 × 107 CFU/mL) were treated for 2 h with
AZM (unlabeled or NBD-tagged), LL-37, or a combination of both, then stained for ﬂuorescence microscopy: FM4-64 (red cell membrane stain), DAPI (blue DNA stain), SYTOX Green
(green DNA stain), and NBD-AZM (green NBD-tagged AZM), “T” denotes toroid shaped nucleoid. (E and G) Bar graphs generated from unbiased software analysis of multiple randommi-
croscopyﬁeldswith N500 cells counted per condition per experimental replicate. Data representative of 3 independent experiments and plotted as themean± SEM.— additionalmicros-
copy details in methods section. ***P b 0.001; one-way ANOVA.
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tion Models
Activity in mammalian culture media and synergy with host AMPs
suggested AZM could be effective against MDR-GNR pathogens
in vivo. AZM concentrates in soft tissues and phagocytes (Amsden,
2001; Girard et al., 1990), pharmacodynamic features providing high
drug levels at infectious foci where endogenous cationic AMPs are de-
ployed. We studied an intratracheal infection model of MDR-AB pneu-
monia with AZM as the sole therapeutic agent. A single subcutaneous
dose of 50 or 100 mg/kg AZM was chosen to achieve serum concentra-
tionsmimicking those found with typical 500 or 1000mg AZM intrave-
nous dosing given to human patients (Beigelman et al., 2009). A single
AZM dose reduced by 2log10 or 99% the amount of MDR AB recovered
from lungs 24 h after challenge (Fig. 4A). Examination of bronchial alve-
olar lavage ﬂuid (BALF) revealed that AZM-treated animals had 50%
fewer neutrophils (alveolar macrophages unchanged) (Fig. 4B), signiﬁ-
cantly reduced pro-inﬂammatory cytokines IL-1β, IL-6, and MIP-2
(Fig. 4C), and histological evidence of reduced neutrophil and bacterial
inﬁltrations (Fig. 4D and E). Increasing the inoculum ofMDR-AB 10-fold
produced signiﬁcantmortalitywithin 48 h. One dose of 100mg/kg AZM
after initial infection, followed by a second dose at 24 h, improved 5d
survival from 22% to 89% (Fig. 4F). In a subcutaneous foreign bodyinfection model, daily AZM reduced by N90% the quantity of MDR-AB
recovered after 3d (Fig. 4G). Reductions of up to 10-fold in bacterial
counts were also observed for AZM monotherapy in both MDR-KP and
-PA lung infection models (Fig. 4H and I). Low dose colistin therapy
alone did not lead to a signiﬁcant reduction in the amount of MDR AB
recovered from lungs 24 h after challenge. However, when a low dose
of AZMwas combinedwith a lowdose of colistin, a signiﬁcant reduction
in lung bacterial CFU was achieved (Fig. S5).
4. Discussion
The continual emergence and rapid spread of MDR-GNRs in hospi-
tals around the world has alarmed physicians, public health epidemiol-
ogists and government agencies, spurring urgent calls to action (World
Health Organization, 2014; Centers for Disease Control and Prevention,
2013). Due to historical precedent and the intrinsic appeal of a “gold
standard”, a single bioassay, the MIC performed in bacteriological
media, has come to dominate evaluation of antibiotic efﬁcacy, from
the earliest stages of the drug development process, to management
of patients based on clinical isolate testing, to establishment of hospital
formularies. However, even before the ﬁrst diagnostic encounter with a
physician, a patient's infection is already being combatted by numerous
endogenous antimicrobial components, including cationic AMPs of the
Fig. 4.AZM activity asmonotherapy againstMDR-GNRs in vivo. (A) C57BL/6J micewere infected intratracheally (i.t.) withMDR AB. Lungs homogenized at 24 h; n=16 for PBS control, 17
for AZM 50 mg/kg, and 16 for AZM 100 mg/kg. (B) Wright–Giemsa stained BALF from C57BL/6J mice infected i.t. with AB. Total neutrophils and macrophages enumerated by light
microscopy+ hemocytometer counts; n= 19 PBS control and 20 AZM 100mg/kg-treatedmice. PMN= polymorphonuclear leukocyte/neutrophil, Mac=macrophage. (C) ELISA detec-
tion of inﬂammatory cytokines in theBALF ofmice from (b). (D and E) LightmicroscopyofWright–Giemsa stained BALF ofmice from (b);Mac=alveolarmacrophage; PMN=neutrophil.
(F) Survival of C57BL/6J mice infected i.t. with 6 × 107 CFU of AB. Mice received two total doses of AZM versus PBS spaced 24 h apart. n = 18 PBS control and 18AZM 100 mg/kg-treated
mice. (G) 1 cm catheter fragment coated with AB was implanted subcutaneously into CD-1 mice; results of 2 independent experiments. N = 10 PBS; 5 AZM 50 mg/kg-treated, 10 Az
100 mg/kg-treated mice (H) CD-1 mice infected i.t. with MDR KP. Lungs homogenized at 36 h. N = 24 PBS control, 23 AZM 50 mg/kg-treated, and 16 AZM 100 mg/kg-treated mice
(i) CD-1 mice infected i.t. with MDR PA. Lungs homogenized at 36 h; results of 2 independent experiments. n = 16 PBS control and 16 AZM 50 mg/kg-treated mice. Data plotted as
mean ± S.E.M. of 3 independent experiments unless otherwise stated. For in vivo mouse studies, AZM was dosed subcutaneously once every 24 h. Dashed line “start” denotes the initial
inoculum. *P b 0.05 **P b 0.01 ***P b 0.001; one-way ANOVA in vivo studies, log-rank test for survival, two-tailed Student's t test in vitro studies.
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of pharmaceutical antibiotics in the richer context of these host defense
factors.
Using traditional susceptibility testing methods, the familiar antibi-
otic AZM shows negligible activity against MDR-GNRs. A small number
of prior studies examining multiple combinations of antibiotics in vitro
have provided clues that AZM can exhibit activity against GNRs
(Appleman et al., 2000; Timurkaynak et al., 2006) or synergize with a
polymyxin type antibiotic (Vaara et al., 2010), but without mechanistic
or in vivo analysis or suggestions of clinical application. To this day, AZM
remains excluded from the antibiotic testing panel reported to physi-
cians when such bacteria are recovered from the blood, sputum or
urine of hospitalized patients. Here we show that AZM has potent bac-
tericidal activity against representative strains of the most fearsome
MDR-GNRs when tested in eukaryotic cell media (+/− human
serum) and in vivo murine models of infection. AZM entry and activity
against MDR-GNRs is synergistically enhanced when the bacterial
outer membrane is perturbed by cationic human AMP LL-37 or by the
last-line antibiotic colistin. Because mutation of the oprM efﬂux pump
system in P. aeruginosa has been associated with increased AZM sensi-
tivity, and protein synthesis inhibition by AZM can reduce oprM gene
expression (Buyck et al., 2012), the enhanced entry of AZM ineukaryotic media and in synergy with colistin or LL-37 that we have
demonstratedmay initiate a positive feedback loop to increase effective
intracellular levels of the antibiotic.
Of note, AZM is touted to have anti-inﬂammatory effects in lung tis-
sues during infection (Yamada et al., 2013), and several studies of short-
or long-term AZM administration in patients with cystic ﬁbrosis, a dis-
ease characterized by chronic recurrent pulmonary infection with PA
and other MDR-GNR bacterial pathogens, have shown reductions in ex-
acerbations and improvement in respiratory capacity (reviewed in
Zarogoulidis et al., 2012). Our ﬁndings raise the possibility that these
beneﬁts could reﬂect, at least in part, a direct and otherwise unantici-
pated bactericidal activity of thedrug. Themacrolides, and azithromycin
in particular, have a number of reported non-bactericidal properties
that could further complement the in vivo efﬁcacy we observed in our
murine models of infection. For example, against various Gram-
negative organisms, AZM has been shown to impair bacterial bioﬁlms
(Gillis and Iglewski, 2004; Molinari et al., 1993), virulence factor pro-
duction (Molinari et al., 1993), motility (Molinari et al., 1992), quorum
sensing (Hoffmann et al., 2007), and adherence to host epithelial cells
(Baumann et al., 2001; Braga and Piatti, 1993).
The major limitation of this study was the use of murine models of
MDR GNR infection as opposed to human clinical cases. Laboratory
697L. Lin et al. / EBioMedicine 2 (2015) 690–698mice are relatively resistant to infection by human clinical isolates of
MDR GNRs requiring high inocula to create a disease phenotype. Fur-
thermore, young mice with normal immunity were tested, whereas
many human patients that develop MDR GNR infection have multiple
co-morbidities including weakened immunity (e.g., from cancer che-
motherapy) or dependence on amedical device (e.g., mechanical venti-
lator). Future randomized clinical trials will be needed to validate
whether or not AZM has therapeutic efﬁcacy in older and sicker
human patients suffering from MDR GNR infections.
In summary, our studies provide an experimental rationale to fur-
ther explore AZM as adjunctive therapy in MDR-GNR infections. In par-
ticular, we have demonstrated for the ﬁrst time that colistin or LL-37
permeabilization of Gram-negative outer membranes facilitates entry
of the large AZMmolecule. Potentially, additional antibiotics, currently
disregarded for various clinical indications due to poor penetration
into Gram-negative bacterial membranes in standard MIC testing, may
likewise have unrecognized in vivo activitieswhenhost immune factors
perturb bacterial membrane integrity. Most immediately, the AZM syn-
ergy with colistin we demonstrate here may allow lower dose, colistin-
sparing regimens that reduce adverse drug effects. Continued examina-
tion of pharmacodynamic interactions between administered antibi-
otics and endogenous AMPs of the innate immune system may reveal
novel treatment strategies for challenging infections.
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